Valuation: Zai Lab Limited

Market Cap 2.16B 1.9B 1.77B 1.62B 3.04B 209B 3.09B 20.97B 8.19B 102B 8.11B 7.93B 354B P/E 2026 *
-8.68x
P/E 2027 * -10.3x
Enterprise Value 1.72B 1.51B 1.4B 1.29B 2.42B 166B 2.46B 16.67B 6.51B 81.23B 6.44B 6.3B 281B EV / Sales 2026 *
3.83x
EV / Sales 2027 * 2.98x
Free-Float
95.17%
Yield 2026 *
-
Yield 2027 * -
Manager TitleAgeSince
Chief Executive Officer 61 2014-03-31
Director of Finance/CFO 58 2023-07-06
President 62 2022-11-30
Director TitleAgeSince
Chairman 61 2014-03-31
Director/Board Member 83 2016-12-31
Director/Board Member 75 2016-12-31
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-.--% - - 2.16B
+0.63%-3.06%+16.18%-9.78% 66.74B
+1.23%+2.80%+37.51%+202.14% 53.32B
+10.08%+51.80%+51.80%+51.80% 48.12B
-1.32%-7.38%-57.63%-57.10% 38.25B
+0.78%-1.84%+52.49%-27.01% 29.85B
+0.84%+0.36%+66.93%+85.42% 23.51B
-5.17%-12.54%+58.98%-56.04% 21.45B
-1.21%+1.12%+1.98%+170.93% 19.97B
-0.22%-0.95%+61.97%+123.78% 16.38B
Average +0.56%-1.00%+32.25%+53.79% 35.29B
Weighted average by Cap. +1.40%-0.11%+27.80%+49.98%

Financials

2026 *2027 *
Net sales 449M 395M 367M 337M 632M 43.33B 643M 4.36B 1.7B 21.24B 1.68B 1.65B 73.49B 596M 524M 487M 447M 839M 57.51B 853M 5.78B 2.26B 28.19B 2.24B 2.19B 97.55B
Net income -241M -212M -197M -181M -339M -23.26B -345M -2.34B -914M -11.4B -904M -885M -39.46B -156M -138M -128M -117M -220M -15.11B -224M -1.52B -593M -7.41B -587M -575M -25.63B
Net Debt -443M -390M -362M -333M -624M -42.79B -635M -4.3B -1.68B -20.97B -1.66B -1.63B -72.58B -387M -341M -317M -291M -546M -37.39B -555M -3.76B -1.47B -18.33B -1.45B -1.42B -63.42B
Logo Zai Lab Limited
Zai Lab Ltd is a holding company primarily engaged in biopharmaceutical business. The Company is focused on discovering, developing, and commercializing products that address medical conditions with significant unmet needs in the areas of oncology, immunology, neuroscience, and infectious disease. The Company has a series of patented drug candidates from the discovery stage to the late clinical project, including ZEJULA, OPTUNE, QINLOCK, NUZYRA and VYVGART, and others. The Company conducts its businesses within domestic and overseas markets.
Employees
1,784
Trader
Investor
-
Global
-
Quality
ESG MSCI
A